FR2525223B1 - NOVEL DIPHOSPHONIC ACIDS, THEIR SALTS, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THERAPEUTICS - Google Patents

NOVEL DIPHOSPHONIC ACIDS, THEIR SALTS, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THERAPEUTICS

Info

Publication number
FR2525223B1
FR2525223B1 FR8305858A FR8305858A FR2525223B1 FR 2525223 B1 FR2525223 B1 FR 2525223B1 FR 8305858 A FR8305858 A FR 8305858A FR 8305858 A FR8305858 A FR 8305858A FR 2525223 B1 FR2525223 B1 FR 2525223B1
Authority
FR
France
Prior art keywords
therapeutics
salts
application
preparation process
diphosphonic acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR8305858A
Other languages
French (fr)
Other versions
FR2525223A1 (en
Inventor
Sergio Rosini
Giorgio Staibano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto Gentili SpA
Original Assignee
Istituto Gentili SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11171970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2525223(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Istituto Gentili SpA filed Critical Istituto Gentili SpA
Publication of FR2525223A1 publication Critical patent/FR2525223A1/en
Application granted granted Critical
Publication of FR2525223B1 publication Critical patent/FR2525223B1/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/3804Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
    • C07F9/3839Polyphosphonic acids
    • C07F9/3873Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/3804Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
    • C07F9/3839Polyphosphonic acids
    • C07F9/3856Polyphosphonic acids containing halogen or nitro(so) substituents
FR8305858A 1982-04-15 1983-04-11 NOVEL DIPHOSPHONIC ACIDS, THEIR SALTS, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THERAPEUTICS Expired FR2525223B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT8220781A IT1201087B (en) 1982-04-15 1982-04-15 PHARMACOLOGICALLY ACTIVE BIPPHOSPHONES, PROCEDURE FOR THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS

Publications (2)

Publication Number Publication Date
FR2525223A1 FR2525223A1 (en) 1983-10-21
FR2525223B1 true FR2525223B1 (en) 1986-04-25

Family

ID=11171970

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8305858A Expired FR2525223B1 (en) 1982-04-15 1983-04-11 NOVEL DIPHOSPHONIC ACIDS, THEIR SALTS, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THERAPEUTICS

Country Status (12)

Country Link
US (1) US4621077A (en)
JP (1) JPS58189193A (en)
BE (1) BE896453A (en)
CH (1) CH661437A5 (en)
FR (1) FR2525223B1 (en)
GB (1) GB2118042B (en)
HK (1) HK79390A (en)
IT (1) IT1201087B (en)
LU (2) LU84746A1 (en)
MX (1) MX9203428A (en)
NL (5) NL192562C (en)
SE (1) SE463239B (en)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8419489D0 (en) * 1984-07-31 1984-09-05 Leo Pharm Prod Ltd Chemical compounds
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
DE3512536A1 (en) * 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE3540150A1 (en) * 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE3623397A1 (en) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US4963681A (en) * 1987-07-06 1990-10-16 Norwich Eaton Pharmaceuticals, Inc. Process for synthesis of aminomethylene phosphonoalkylphosphinates
IL86951A (en) * 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkyl-phosphinates and pharmaceutical compositions containing them
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5227506A (en) * 1989-09-06 1993-07-13 Merck & Co., Inc. Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
FI83657C (en) * 1989-09-08 1991-08-12 Huhtamaeki Oy Process for the preparation of methylene bisphosphonic acids
US5356887A (en) * 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
GB2248061A (en) * 1990-09-18 1992-03-25 Merck & Co Inc Amino-hydroxy-alkylidene bis phosphonic acids
US5183815A (en) * 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
IT1247034B (en) * 1991-06-26 1994-12-12 Gentili Ist Spa DIMETHYLAMINE-HYDROXY ACIDS DIPHOSPHONICS AND THEIR SALTS, THEIR PRODUCTION PROCESS AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM
US6096342A (en) * 1997-03-12 2000-08-01 The Procter & Gamble Company Dosage forms of risedronate
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
TW237386B (en) * 1992-04-15 1995-01-01 Ciba Geigy
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
US6399592B1 (en) 1992-12-23 2002-06-04 Merck & Co., Inc. Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5591730A (en) * 1993-10-12 1997-01-07 The Regents Of The University Of California Inhibition of urinary calculi growth
US5854227A (en) * 1994-03-04 1998-12-29 Hartmann; John F. Therapeutic derivatives of diphosphonates
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
US5449819A (en) * 1994-06-06 1995-09-12 Merck & Co., Inc. Process for removing waste pox, alendronate and its by products
US6008206A (en) * 1994-09-21 1999-12-28 Merck & Co., Inc. Sodium alendronate preparation for local administration
JP3411690B2 (en) * 1994-09-21 2003-06-03 帝人株式会社 Alendronate sodium preparation for topical administration
US20010051616A1 (en) * 1995-02-17 2001-12-13 David B. Karpf Method of lessening the risk of vertebral fractures
EP0809502A4 (en) * 1995-02-17 2001-12-05 Merck & Co Inc Method of lessening the risk of non-vertebral bone fractures
JPH10506638A (en) * 1995-05-12 1998-06-30 メルク エンド カンパニー インコーポレーテッド Prevention of tooth loss by administration of alendronate or its salt
EP0831756A1 (en) 1995-06-06 1998-04-01 Merck & Co., Inc. Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
EP0837863A4 (en) * 1995-06-06 1999-06-16 Merck & Co Inc Disodium alendronate formulations
DE69634357T2 (en) * 1995-06-06 2006-01-12 Merck & Co., Inc. FORMULATIONS WITH THE WATER-FREE MONONATRIUM SALT OF ALENDRONATE AND THEIR USE FOR THE TREATMENT OF BONE DISEASES
AU712710B2 (en) * 1996-05-17 1999-11-11 Merck Sharp & Dohme Corp. Effervescent bisphosphonate formulation
EP1820497A3 (en) * 1996-05-17 2009-07-22 Merck & Co., Inc. Effervescent bisphosphonate formulation
EP1378234A1 (en) * 1996-05-17 2004-01-07 MERCK & CO. INC. Effervescent bisphosphonate formulation
EE03669B1 (en) * 1996-10-04 2002-04-15 Merck & Co., Inc. Liquid alendronate preparations and method of preparation
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6410782B1 (en) * 1997-07-09 2002-06-25 Geange Ltd. Diphosphonic acid salts for the treatment of osteoporosis
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6416964B2 (en) 1998-01-29 2002-07-09 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
US7598246B2 (en) * 1998-04-02 2009-10-06 Mbc Pharma, Inc. Bisphosphonate conjugates and methods of making and using the same
US8586781B2 (en) 1998-04-02 2013-11-19 Mbc Pharma, Inc. Bone targeted therapeutics and methods of making and using the same
US6750340B2 (en) 1998-04-02 2004-06-15 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
US6896871B2 (en) 1998-04-02 2005-05-24 Mbc Research, Inc. Biphosphonate conjugates and methods of making and using the same
US6214812B1 (en) * 1998-04-02 2001-04-10 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
CA2336201A1 (en) 1998-06-24 1999-12-29 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
US20030078211A1 (en) * 1998-06-24 2003-04-24 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
US6008207A (en) * 1998-08-13 1999-12-28 Merck & Co., Inc. Anhydrous alendronate monosodium salt formulations
SK2482001A3 (en) 1998-08-27 2002-01-07 Teva Pharma Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
CA2363317C (en) * 1999-02-17 2008-04-29 Teva Pharmaceutical Industries, Ltd. Novel process for preparing alendronic acid
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
AR024462A1 (en) 1999-07-01 2002-10-02 Merck & Co Inc PHARMACEUTICAL TABLETS
SE9903345D0 (en) * 1999-09-17 1999-09-17 Astra Pharma Prod Novel process
KR100317935B1 (en) * 1999-10-20 2001-12-22 유승필 Pharmaceutical compositions and preparations for treatment of metabolic bone disease
AR021347A1 (en) 1999-10-20 2002-07-17 Cipla Ltd A PHARMACEUTICAL COMPOSITION CONTAINING SISPHOSPHONIC ACID (S) OR SALT (S) OF THE SAME AND A PREPARATION PROCESS OF THE SAME
US6677320B2 (en) 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
US6562974B2 (en) 2000-02-01 2003-05-13 The Procter & Gamble Company Process for making geminal bisphosphonates
US6410520B2 (en) 2000-02-01 2002-06-25 The Procter & Gamble Company Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
US6468559B1 (en) 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
US20040038946A1 (en) * 2001-04-27 2004-02-26 Wilson Lon J. Fullerene-based drugs targeted to bone
CN100345549C (en) * 2001-05-02 2007-10-31 诺瓦提斯公司 Method of administration of bisphosphonates by inhalation in the treatment or prevention of bone resorption and osteoporosis
US20030216358A1 (en) * 2001-07-05 2003-11-20 Muchmore Douglas Boyer Method for enhancing bone mineral density gain
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
AU2002360619B2 (en) * 2001-12-21 2006-10-05 Allergan Pharmaceuticals International Limited Method for the treatment of bone disorders
CN1649614A (en) 2002-02-22 2005-08-03 新河药品股份有限公司 Active agent delivery systems and methods for protecting and administering active agents
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
EP1494683A1 (en) * 2002-04-05 2005-01-12 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
ITMI20020908A1 (en) * 2002-04-29 2003-10-29 Chemi Spa ALENDRONATE SODIUM PREPARATION PROCESS
RU2329809C2 (en) 2002-05-10 2008-07-27 Ф.Хоффманн-Ля Рош Аг Applications of bisphosphonic acids for osteoporosis treatment and prevention
CN1665825A (en) * 2002-05-17 2005-09-07 特瓦制药工业有限公司 Use of certain diluents for making bisphosphonic acids
US20040137058A1 (en) * 2002-07-09 2004-07-15 Katdare Ashok V. Effervescent bisphosphonate formulation
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
MXPA04010866A (en) * 2002-12-20 2005-01-25 Hoffmann La Roche High dose ibandronate formulation.
US20040206932A1 (en) 2002-12-30 2004-10-21 Abuelyaman Ahmed S. Compositions including polymerizable bisphosphonic acids and methods
CN1325506C (en) * 2003-05-15 2007-07-11 中国科学院上海药物研究所 Allan phosphonic acid as bone re-absorption inhibitor and its physiologically acceptable salt and their prepn
EP2279722B1 (en) * 2003-08-12 2013-05-01 3M Innovative Properties Company Self-etching dental compositions and its use
KR20060058134A (en) * 2003-09-19 2006-05-29 화이자 프로덕츠 인코포레이티드 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
SI1753395T1 (en) 2004-05-24 2011-01-31 Warner Chilcott Co Llc Enteric solid oral dosage form of a bisphosphonate containing a chelating agent
KR100564628B1 (en) * 2004-06-16 2006-03-28 삼성전자주식회사 Split gate type flash mwmory device and method of manufacturing the same
AU2005269869B2 (en) 2004-07-08 2011-12-01 3M Innovative Properties Company Dental methods, compositions, and kits including acid-sensitive dyes
WO2006020760A1 (en) 2004-08-11 2006-02-23 3M Innovative Properties Company Self-adhesive compositions including a plurality of acidic compounds
WO2006039721A2 (en) * 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
CN1304401C (en) * 2004-12-28 2007-03-14 浙江工业大学 Method for preparing Alendronic acid
EA200701997A1 (en) * 2005-03-17 2008-02-28 Элан Фарма Интернэшнл Лтд. COMPOSITION OF BISPHOSPHONATE NANOPARTICLES
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
US20070087052A1 (en) * 2005-10-19 2007-04-19 Katdare Ashok V Effervescent bisphosphonate formulation
DE112007000280A5 (en) 2006-02-03 2008-10-30 HÄRING, Thomas Phosphonic acid-containing blends and phosphonic acid-containing polymers
AU2007226964B2 (en) * 2006-03-17 2012-03-22 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
WO2008063865A2 (en) * 2006-11-21 2008-05-29 Teikoku Pharma Usa, Inc. Biphosphonate inhalant formulations and methods for using the same
JP5507256B2 (en) 2006-12-13 2014-05-28 スリーエム イノベイティブ プロパティズ カンパニー Method of using a dental composition having an acidic component and a photobleachable dye
US20080182823A1 (en) * 2007-01-26 2008-07-31 Hidesmasa Katsumi Polymer-linked-biophosphonate inhalant formulations and methods for using the same
WO2009105140A2 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
US20090197837A1 (en) * 2008-02-05 2009-08-06 Desai Vivek S Alendronate formulations, method of making and method of use thereof
US7964584B2 (en) * 2008-08-01 2011-06-21 Dong Wha Pharmaceutical Co., Ltd. Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmaceutical composition comprising benzamidine derivatives or their salts, and alendronic acid or its salt
US20100034752A1 (en) * 2008-08-11 2010-02-11 Toru Hibi Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same
FR2954320B1 (en) 2009-12-17 2012-06-15 Cll Pharma SUPPLEMENTALLY AVAILABLE ORAL PHARMACEUTICAL COMPOSITION CONTAINING BIPHOSPHONIC ACID OR ONE OF ITS SALTS
US9334300B2 (en) 2011-08-01 2016-05-10 Mbc Pharma, Inc. Vitamin B6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
EP3623364A1 (en) 2014-02-13 2020-03-18 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
PL407922A1 (en) 2014-04-16 2015-10-26 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością New bisphosphonates and their applications
US9994600B2 (en) 2014-07-02 2018-06-12 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143123A (en) * 1966-05-18 1969-02-19 Albright & Wilson Mfg Ltd Phosphate compositions
GB1235029A (en) * 1966-12-29 1971-06-09 Procter & Gamble Stannous polyphosphonates and their use in oral compositions for caries prophylaxis
PH9776A (en) * 1967-12-11 1976-03-17 M Francis Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue and method of use
US3683080A (en) * 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
PH9853A (en) * 1972-06-08 1976-04-13 M Francis Compositions for inhibiting mobilization of calcium phosphate in animal tissue and method of use thereof
IE37842B1 (en) * 1972-06-30 1977-10-26 Procter & Gamble Oral compositions for plaque caries and calculus retardation with reduced staining tendencies
IE39282B1 (en) * 1973-05-23 1978-09-13 Procter & Gamble Radionuclide labelled phosphonic acids for the treatment of calcific tumors
DE2405254C2 (en) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Use of 3-amino-1-hydroxypropane-1, 1-diphosphonic acid or its water-soluble salts for influencing calcium metabolic disorders in the human or animal body
US3987157A (en) * 1974-08-29 1976-10-19 Union Carbide Corporation Technetium 99-m labeled radio-diagnostic agents employing stannous tartrate and method of preparation
DE2534391C2 (en) * 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkane-1,1-diphosphonic acids
JPS5283957A (en) * 1975-12-01 1977-07-13 Henkel & Cie Gmbh Medicine for treating metabolic obstruction of calcium
US4137309A (en) * 1976-10-14 1979-01-30 The Procter & Gamble Company Therapeutic treatment
US4275059A (en) * 1977-03-28 1981-06-23 The Procter & Gamble Company Salicylate anti-inflammatory composition
US4216211A (en) * 1977-10-31 1980-08-05 The Procter & Gamble Company Therapeutic composition
US4230700A (en) * 1977-12-07 1980-10-28 The Procter & Gamble Company Methods for inhibiting mobilization of calcium phosphate in animal tissue
US4330537A (en) * 1977-12-07 1982-05-18 The Procter & Gamble Company Compositions for inhibiting mobilization of calcium phosphate in animal tissue
US4216212A (en) * 1978-06-08 1980-08-05 The Procter & Gamble Company Pyrazolidine anti-inflammatory composition and methods of use
IT1097292B (en) * 1978-06-27 1985-08-31 Gentili Ist Spa PHARMACEUTICAL COMPOSITION FOR THERAPY OF NON-NEOPLASTIC OBSTRUCTIVE YELLOW
US4264582A (en) * 1978-07-31 1981-04-28 The Procter & Gamble Company Isobutylphenylacetate anti-inflammatory composition
US4282214A (en) * 1978-07-31 1981-08-04 The Procter & Gamble Company Phenylacetate anti-inflammatory composition
US4254114A (en) * 1979-01-02 1981-03-03 The Proctor & Gamble Company Control of pyrophosphate microorganisms with organophosphonates
GB2043072B (en) * 1979-02-13 1983-11-23 Symphar Sa Diphosphonate compounds
GB2076889B (en) * 1980-03-12 1983-10-26 Cadbury Schweppes Transport Feeding fuel and water emulsion i c engines
DE3016289A1 (en) * 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf METHOD FOR PRODUCING OMEGA-AMINO-1-HYDROXYALKYLIDEN-1,1-BIS-PHOSPHONIC ACIDS
GB2079285B (en) * 1980-07-09 1984-05-23 Symphar Sa Dipthosphonate derivatives and pahrmaceutical compositions containing them
GB2082585A (en) * 1980-08-27 1982-03-10 Vysoka Skola Chem Tech 6-amino-1-hydroxyhexylidene diphosphonic acid, salts thereof and a method of producing the acid and salts.
JPS5759900A (en) * 1980-09-29 1982-04-10 Vysoka Skola Chem Tech 6-amino-1-hydroxyhexylidene diphosphonic acid
BE890453A (en) * 1980-10-07 1982-03-22 Procter & Gamble PROCESS FOR INHIBITING TUMOR CELL METASTASES
US4330530A (en) * 1980-12-22 1982-05-18 The Procter & Gamble Company Anti-arthritic compositions and method using gold salts and organophosphonates
IT1194748B (en) * 1981-02-12 1988-09-28 Gentili Ist Spa PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OSTEOPATHIES

Also Published As

Publication number Publication date
LU84746A1 (en) 1983-11-17
IT1201087B (en) 1989-01-27
SE463239B (en) 1990-10-29
MX9203428A (en) 1992-07-01
GB8308791D0 (en) 1983-05-11
BE896453A (en) 1983-08-01
FR2525223A1 (en) 1983-10-21
US4621077A (en) 1986-11-04
GB2118042B (en) 1986-01-15
NL980005I1 (en) 1998-04-01
NL980004I1 (en) 1998-04-01
IT8220781A0 (en) 1982-04-15
NL970038I1 (en) 1998-01-05
NL8301324A (en) 1983-11-01
JPS58189193A (en) 1983-11-04
LU88714I2 (en) 1996-08-23
SE8302130L (en) 1983-10-16
NL980010I1 (en) 1998-05-06
CH661437A5 (en) 1987-07-31
NL192562C (en) 1997-10-03
NL192562B (en) 1997-06-02
SE8302130D0 (en) 1983-04-15
HK79390A (en) 1990-10-12
NL970038I2 (en) 2000-11-01
GB2118042A (en) 1983-10-26
JPH0213645B2 (en) 1990-04-04

Similar Documents

Publication Publication Date Title
FR2525223B1 (en) NOVEL DIPHOSPHONIC ACIDS, THEIR SALTS, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THERAPEUTICS
BE892270A (en) NOVEL AMINOMETHYL-5 OXAZOLIDINIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC APPLICATION
BE896009A (en) NOVEL ARYLIC DERIVATIVES OF PIPERAZINE, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS
FR2514350B1 (en) N- (4- (3-AMINOPROPYL) AMINOBUTYL) -2- (O-GUANIDINO (FATTY ACID) AMIDO) -ETHANAMIDES SUBSTITUTED IN POSITION 2 AND THEIR SALTS, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
LU76848A1 (en) NEW HYDROXYMETHYL-5 OXAZOLIDINONE-2, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2326922A1 (en) NEW PILOCARPINE SALTS AND THEIR PREPARATION PROCESS
FR2522324B1 (en) PYRROLE-ACETAMIDES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITION CONTAINING THEM
FR2569183B1 (en) INDANE DERIVATIVES AND THEIR SALTS, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION
BE882764A (en) PENEME-3-CARBOXYLIC ACID DERIVATIVES, PREPARATION METHODS THEREOF AND THERAPEUTIC APPLICATION THEREOF
FR2348907A1 (en) POLYPRENYL DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THERAPEUTICS
MA19331A1 (en) THIENO - PYRIDINONE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION.
FR2543140B1 (en) NOVEL FLAVONE-CARBOXYLIC ACIDS-4 ', THEIR PREPARATION METHOD AND THEIR APPLICATION IN THERAPEUTICS
FR2502626B1 (en) OXAZAPHOSPHORIN-4-THIO-ALCANESULFONIC ACIDS, THEIR NEUTRAL SALTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
BE858356A (en) 7-ACYLAMINO-8-OXO-3-OXA-1-AZABICYCLO- (4.2.0) OCTANE-2-CARBOXYLIC ACID, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION
FR2529545B1 (en) NOVEL CARNITINE SALTS AND THEIR PREPARATION PROCESS
FR2477536B1 (en) NOVEL ACYLATED CARNITINE DERIVATIVES, PROCESS FOR PREPARING THESE DERIVATIVES AND THEIR THERAPEUTIC USE
BE884782A (en) NOVEL ALCOXYBENZOFURANNE-2-CARBOXYLIC ACIDS, SALTS AND ESTERS THEREOF, ESPECIALLY USEFUL AS HYPOLIPEMIATING AGENTS, AND PROCESS FOR THEIR PREPARATION
BE895445A (en) DIHYDRO- AND TETRAHYDROMONACOLINS L, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN TJERAPEUTICS
BE864111A (en) PYRAZOLO-OXAZEPINES AND PYRAZOLO-THIAZEPINES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS IN THERAPEUTICS
FR2514768B1 (en) PHOSPHORAMIDE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION
FR2477142B1 (en) NOVEL NITROSOUREE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION
LU79016A1 (en) IMIDAZOLE-METHYLPHOSPHONIUM SALTS, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS
FR2497668B1 (en) INJECTABLE LIPOPROTEIC EMULSIONS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC APPLICATIONS
BE866565A (en) 5-SULFAMOYL-ORTHANILIC ACIDS THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATIONS
BE862878A (en) ALKYLTHIO-7,8-DIHYDROXY-1-PHENYL-2,3,4,5, -TETRAHYDRO-1H-3-BENZAZEPINES, THEIR PREPARATION PROCESS AND THERAPEUTIC APPLICATION

Legal Events

Date Code Title Description
CP Supplementary protection certificate (spc) filed

Free format text: PRODUCT NAME: ALENDRONATE MONOSODIQUE; NAT. REGISTRATION NO/DATE: NL 20330 19960606; FIRST REGISTRATION: IT - 29052014 19930716

Spc suppl protection certif: 96C0032

Filing date: 19960909

CP Supplementary protection certificate (spc) filed

Free format text: 96C0032, 960909

CR Request for supplementary protection certificate laid open to the public (eec regulation of 18 june 1992)

Free format text: 96C0032, 960909

CY Supplementary certificate of protection granted (eec regulation of 18 june 1992)

Free format text: 96C0032, 960909, EXPIRES: 20080410

CP Supplementary protection certificate (spc) filed
TP Transmission of property